期刊文献+

扩张型心肌病治疗手段的进展 被引量:13

Advances in treatment of dilated cardiomyopathy
下载PDF
导出
摘要 扩张型心肌病(DCM)定义为单侧或双侧心腔扩大,伴有心肌肥厚,心肌收缩功能减退,伴或不伴有心力衰竭。目前该病发病率高,病因不明,致死率较高,无特效治疗手段,预后极差,严重危害着人类的健康。为此,本文针对DCM目前的治疗方法进行系统的综述。 Dilated cardiomyopathy (DCM) is defined as a unilateral or bilateral expanded chambers of the heart accompanied by cardiac hypertrophy and myocardial systolic dysfunction, with or without heart failure. The incidence of DCM increases gradually, with the cause being unknown and without specific treatment. Mortality rate is higher and prognosis is poorer, and human health is being seriously compro- mised. This article systematically reviews current methods of treatment for DCM.
出处 《心脏杂志》 CAS 2016年第4期488-491,共4页 Chinese Heart Journal
关键词 扩张型心肌病 治疗 研究进展 综述 dilated cardiomyopathy therapy progress review
  • 相关文献

参考文献26

  • 1Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies : an American Heart Asso- ciation Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomies and Translational Biol- ogy Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[ J]. Circulation, 2006, 113(14) :1807 - 1816.
  • 2Taylor DO, Edwards LB, Boucek MM, et al. Registry of the Interna- tional Society for Heart and Lung Transplantation: twenty-fourth offi- cial adult heart transplant report-2007[ J ]. J Heart Lung Trans- plant, 2007, 26(8):769-781.
  • 3Spinarova L, Spinar J. Pharmacotherapy of dilated eardiomyopathy [J]. Curr Pharrn Des, 2015, 21(4) :449 -458.
  • 4Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guide- line for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16) :e240 - e327.
  • 5Kaya MG, Sarli B, Akpek M, et al. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated eardiom~opath3~ : A randomi~d trial of car~edild and meto- prolol[J]. Cardiol J, 2014, 21(4):434-441.
  • 6Matsumura Y, Hoshikawa-Nagai E, Kubo T, et al. Prediction of left ventricular reverse remodeling after therapy with angiotensin-conver- ting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy [ J ]. Car- diovasc Ultrasound, 2015, 13:14.
  • 7Hu LJ, Chen YQ, Deng SB, et al. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis [ J ]. Br J Clin Pharmacol, 2013,75 (5) : 1202 - 1212.
  • 8Traynor K. Ivabradine approved for stable chronic heart failure [ J ]. Am J Health Syst Pharm, 2015, 72(11) :896.
  • 9Utter MS, Ryha DM, Li BH, et al. Omecamtiv mecarbil, a cardiac myosin activator, increases Ca2 + -sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomyosin E54K [ J ]. J Cardiovasc Pharmacol, 2015, Jun 9. [Epub ahead of print].
  • 10Carmo P, Nogueira G, Anjos R, et al. [ Upgrading to biventricular pacing for dilated cardiomyopathy following right ventricular pacing in a young patient] [J~. Rev Port Cardiol, 2012, 31(1) :43 -47.

同被引文献106

引证文献13

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部